

Iowa Medicaid Drug Utilization Review (DUR) Commission

May 5, 2021

Location: Teleconference (Due to COVID-19)

Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m3a792adfd92a3ebb7bca62b8ec474702>

Dial In: 1-844-245-7693

Meeting Number: 130 558 0415

Meeting Password: UQux5ZG5tm8

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) March 2021 DUR Recommendation Letter to DHS
 - c) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Iowa Total Care
 - b) Fee-for-Service
 - c) Amerigroup
 - d) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure.
 - Written - Must submit written comments and a completed conflict of interest disclosure.
 - Reference complete public comment policy [here](#).
 - **All submissions must be received no later than 4:30 p.m. CT April 28, 2021.**
 - Send to info@iadur.org **Indicate in email if providing written comment or verbal comment.**
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Concurrent Opioids and Benzodiazepines – Updated Data
 - ii. Duplicate Therapy – Benzodiazepines

- iii. Single Ingredient Buprenorphine
- b) Proposal(s)
 - i. Montelukast for Allergic Rhinitis
 - ii. GERD and PPI Therapy
- c) Commission Recommendations for Retrospective DUR Agenda Topics
- 7. Prospective DUR
 - a) Budesonide/Formoterol Inhalation Aerosol & Mometasone/Formoterol Inhalation Aerosol
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Proton Pump Inhibitors – Initial Review
 - b) Valsartan/Sacubitril (Entresto) – Initial Review
 - c) Initial Days Supply Limit Override – Initial Review
 - d) Mannitol Inhalation Powder (Bronchitol) – Initial Review
 - e) Vesicular Monoamine Transporter (VMAT) 2 Inhibitors – Initial Review
 - f) Risdiplam (Evrysdi) – Second Review
 - g) Binge Eating Disorder – Second Review
 - h) IL-5 Antagonists – Second Review
 - i) Isotretinoin (Oral) – Second Review
 - j) Multiple Sclerosis Agents, Oral –Second Review
 - k) Nonsteroidal Anti-Inflammatory Drugs – Second Review
 - l) Alpha₂ Agonists, Extended Release – Removal of Criteria – Second Review
- 10. Miscellaneous
 - a) DUR Digest Vol. 33, No. 2 – Initial Review
 - b) MedWatch
 - [FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart](#)
 - [FDA Approves New indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients](#)
 - [Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine \(Lamictal\) in patients with heart disease](#)
 - [FDA approves add-on therapy for patients with genetic form of severely high cholesterol](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to

Next Meeting
August 4, 2021
Location TBD

the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

**Next Meeting
August 4, 2021
Location TBD**